🇺🇸 FDA
Patent

US 9486456

Treatment of esophageal motility disorder using sepiapterin, tetrahydrobiopterin and derivatives thereof

granted A61KA61K31/4985A61K31/519

Quick answer

US patent 9486456 (Treatment of esophageal motility disorder using sepiapterin, tetrahydrobiopterin and derivatives thereof) held by The Board of Regents of the University of Texas System expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Nov 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61K, A61K31/4985, A61K31/519, A61K45/06, A61P